APGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Apogee Therapeutics Inc (APGE) is not a strong buy for a beginner, long-term investor at this moment. While analysts maintain buy ratings with high price targets, the recent insider selling, lack of immediate positive catalysts, and neutral technical indicators suggest waiting for more clarity or a better entry point.
The MACD is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 61.621, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 68.942), suggesting limited immediate upside potential.
based on promising drug pipeline data. Citi and UBS view the recent selloff as an overreaction and a buying opportunity.
Insider selling by an officer (60,000 shares recently) and no recent congress trading data. The stock has a 50% chance of declining in the next week and month, with a lack of strong technical signals.
In Q3 2025, revenue remained at $0, net income improved by 32.65% YoY to -$65.02M, and EPS increased by 29.07% YoY to -1.11. While losses are narrowing, the company is not yet profitable.
Analysts generally maintain buy ratings with high price targets (up to $137). However, RBC downgraded the stock to Sector Perform due to valuation concerns, citing a crowded market and limited near-term upside after a 108% 12-month gain.
